Резултати
eNauka >
Results >
HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
| Title: | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome | Authors: | Tobias, Joshua; Kundi, Michael; Garner-Spitzer, E; Zielinski, Christoph; Maglakelidze, Marina; Andric, Zoran G   ; Petrovic, Z; Nagarkar, R; Chawla, T; Chong, LO; |
Issue Date: | 2023 | Publication: | ANNALS OF ONCOLOGY | ISSN: | 0923-7534 Annals of Oncology Search Idenfier |
Type: | Conference Paper | Collation: | vol. 34 str. S864-S864 | DOI: | 10.1016/j.annonc.2023.09.1448 | WoS-ID: | 001087480202209 | URI: | https://enauka.gov.rs/handle/123456789/935339 | Metadata source: | (Preuzeto iz Nasi u WoS) | M-category: | Mp. category will be shown later |
Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.